SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Healthcare >

Acasti Pharma, Inc (ACST)

ACST RSS Feed
Add ACST Price Alert      Hide Sticky   Hide Intro
Moderator: I.B.Broke
Search This Board: 
Last Post: 9/25/2017 7:43:58 PM - Followers: 37 - Board type: Free - Posts Today: 0

Acasti Pharma is a biopharmaceutical innovator advancing a potentially best-in-class cardiovascular drug, CaPre®, for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one-third of the U.S. population.

Established in August 2008, Acasti is focused on addressing an important market need for an effective, safe and well-absorbed omega-3 therapeutic that can address a patient’s lipid profile — making a positive impact on the major lipids associated with cardiovascular disease risk.


 
 


President and CEO 
Jan D'Alvise
LinkedIn


 

Acasti’s Phase 3-ready investigational candidate CaPre® will be the first pharmaceutical omega-3 product sourced from krill oil. CaPre® has successfully completed phase 1 and 2 trials for the treatment of hypertriglyceridemia, a common metabolic condition characterized by high levels of triglycerides in the blood stream.

The American Heart Association has estimated that one-third of the U.S. population has elevated levels of triglycerides.

 

CaPre’s concentrated omega-3s from krill oil are absorbed into the body more efficiently than those from fish oils, enhancing bioavailability and providing benefits to a patient’s total lipid profile. That means that CaPre® doesn’t just lower triglycerides; it also has shown in clinical trials to have beneficial effects on “good” and “bad” cholesterol levels that affect heart health.
 


Laval, Québec, CANADA, Sept. 14, 2016 Acasti Pharma (NASDAQ:ACST TSX-V:APO) today announced that its bridging study for novel drug candidate CaPre® (omega-3 phospholipid) has successfully met its objectives, supporting Acasti’s strategy to pursue the U.S. Food and Drug Administration’s (FDA) 505(b)(2) regulatory pathway for approval. Acasti is developing CaPre for the treatment of patients with severe hypertriglyceridemia, a metabolic condition that contributes to increased risk of cardiovascular disease and pancreatitis. The 505(b)(2) regulatory pathway allows Acasti to streamline the overall development program required to support a New Drug Application (NDA) by relying on the safety data of an approved drug. 



Laval, Québec, CANADA, October 26, 2016 — Acasti Pharma (NASDAQ:ACST TSX-V:APO) today announced that the United States Patent and Trademark Office issued Acasti a patent (U.S. patent no. 9,475,830) directed to a method of treating hypertriglyceridemia by the administration of a concentrated phospholipid composition. 
This newly issued patent expands Acasti’s intellectual property portfolio related to concentrated therapeutic phospholipid omega-3 compositions covering methods for treating or preventing diseases associated with or related to cardiovascular disease. 

 
 


 







SureTrader
Interactive Brokers Advertisement
ACST
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ACST News: Report of Foreign Issuer (6-k) 10/05/2017 06:03:09 AM
ACST News: Securities Registration (foreign Private Issuer) (f-1) 09/29/2017 05:29:04 PM
ACST News: Report of Foreign Issuer (6-k) 09/01/2017 06:04:58 AM
ACST News: Report of Foreign Issuer (6-k) 08/25/2017 07:32:05 AM
ACST News: Report of Foreign Issuer (6-k) 08/17/2017 08:43:21 AM
PostSubject
#290  Sticky Note CaPre progression and expected launch schedule I.B.Broke 09/25/17 07:43:57 PM
#290   CaPre progression and expected launch schedule I.B.Broke 09/25/17 07:43:57 PM
#289   Acasti reports 1Q loss I.B.Broke 08/15/17 11:43:04 AM
#288   We sustained our positive business performance in the I.B.Broke 08/15/17 11:40:46 AM
#287   Acasti Pharma Reports First Quarter FY 2018 Financial Results I.B.Broke 08/15/17 11:38:32 AM
#286   Vote Recieved in mail vote for Directors and more PJO 07/28/17 02:46:55 PM
#285   Acasti Pharma Inc (ACST) Sees RMI Trending Upward I.B.Broke 07/28/17 10:07:53 AM
#284   Acasti Pharma Announces Issuance of Common Shares in I.B.Broke 07/28/17 10:05:41 AM
#283   CORRECTION: Acasti Pharma Grants Stock Options I.B.Broke 06/16/17 05:52:58 PM
#282   Acasti Pharma Grants Stock Options I.B.Broke 06/15/17 09:02:19 AM
#281   Acasti and CordenPharma look to continuous production for I.B.Broke 06/13/17 08:12:33 PM
#280   Acasti Pharma To Present at Upcoming International Industry Conferences I.B.Broke 06/12/17 12:13:23 PM
#279   Acasti Pharma and CordenPharma Announce Large Scale Production I.B.Broke 05/31/17 07:28:01 PM
#278   Acasti Granted Additional Composition & Use Patents in I.B.Broke 04/25/17 05:42:25 PM
#277   Acasti Pharma to Present CaPre Omega-3 Bridging Study I.B.Broke 04/14/17 09:12:29 PM
#276   Acasti Pharma Provides Update On CaPre Phase 3 I.B.Broke 03/30/17 05:44:39 PM
#275   Phase 3 news PJO 03/30/17 10:21:57 AM
#274   HAYWOOD GEORGE WEAVER has filed a new 13G, wiltonio 03/22/17 04:34:58 PM
#273   Acasti Pharma Forms Scientific Advisory Board and Appoints I.B.Broke 03/08/17 06:25:18 PM
#272   Corporation prepares to advance CaPre®, its krill-based omega-3 I.B.Broke 02/25/17 04:17:09 PM
#271   Acasti Pharma Grants Incentive Stock and Options I.B.Broke 02/25/17 04:15:50 PM
#270   Acasti Pharma Announces Closings of Concurrent Public Offering I.B.Broke 02/24/17 11:27:05 AM
#269   Acasti Pharma Announces Pricing for its Public Offering I.B.Broke 02/13/17 06:59:52 PM
#268   Acasti Pharma Announces Proposed Private Placement of Convertible I.B.Broke 02/02/17 06:52:32 PM
#267   * * $ACST Video Chart 12-23-16 * * ClayTrader 12/23/16 04:22:57 PM
#266   Sounds Fishy to me -Advanced Krill fish oil shurtha2000 12/23/16 10:24:59 AM
#265   * * $ACST Video Chart 11-29-16 * * ClayTrader 11/29/16 05:16:13 PM
#264   First good pick in a while of momentumotc newsletter GoodWill 11/29/16 09:50:24 AM
#263   Acasti Pharma Appoints Linda O’Keefe as Chief Financial Officer. I.B.Broke 11/28/16 06:18:54 PM
#262   “This patent furthers our strategy to build and I.B.Broke 10/26/16 10:50:59 PM
#261   Acasti Pharma Builds Intellectual Property Portfolio with Newly I.B.Broke 10/26/16 09:23:27 PM
#260   Volume in September of this year was caused I.B.Broke 10/24/16 04:55:20 PM
#259   Acasti Pharma Reports Second Quarter 2017 Financial Results I.B.Broke 10/11/16 08:25:03 PM
#258   "We think there’s a lot of potential here, ash111 10/06/16 01:37:34 PM
#256   large bids into close.light accumulation due to tiny float ash111 09/26/16 03:58:41 PM
#255   GSK is a $105B Co. Results from a ash111 09/16/16 04:11:11 PM
#254   15k in bids.nice volume.accumulation still going ash111 09/16/16 02:42:32 PM
#253   have noticed the potential too. ash111 09/15/16 04:32:50 PM
#252   One of few stocks I'm loading up on Chuck87 09/15/16 04:27:43 PM
#251   ACST 10.7m O/S, 5.2m float.that's very impressive: Acasti ash111 09/15/16 12:22:31 PM
#250   agree.cap is only $23m. ash111 09/15/16 10:01:16 AM
#249   Moving again this morning! Curt D 09/15/16 09:34:21 AM
#248   http://www.smart-publications.com/articles/pharmaceutical-sales-of-omega-3-fatty Chuck87 09/15/16 07:24:56 AM
#247   http://www.acastipharma.com/research-and-innovation/ Huge opportunity Will rep Chuck87 09/14/16 11:00:45 PM
#246   $ACST TA video Shortmetina 09/14/16 07:42:17 PM
#245   * * $ACST Video Chart 09-14-16 * * ClayTrader 09/14/16 04:53:58 PM
#244   Great results in a study. Beats out Lovaza Chuck87 09/14/16 04:45:58 PM
#243   Yep , I didn't pull the trigger at Yo-Yo 09/14/16 04:43:17 PM
#242   ACST another massive runner from open to close! cjstocksup 09/14/16 04:41:00 PM
#241   Lmao !!! Yo-Yo 09/14/16 03:09:27 PM
#240   A 6k lol ©PROPHETABLE 09/14/16 03:08:50 PM
PostSubject